Companies: 10,795·Total market cap: $144.5T
Mosaic ImmunoEngineering Inc.

Mosaic ImmunoEngineering Inc.

CPMVOTCHealthcare● Active
$0.69
+$0.02(+3.03%)
Market Cap$5028940
P/E Ratio
52W High$1.05
52W Low$0.3
Overview

Mosaic ImmunoEngineering Inc. (CPMV) Revenue

Annual & quarterly revenue history · segment & region breakdown

CPMV · revenue · updated Jun 9, 2026

Core revenue metrics

Mosaic ImmunoEngineering Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
2 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Mosaic ImmunoEngineering Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
CPMV revenue by year · CPMV revenue history · CPMV annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Mosaic ImmunoEngineering Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Mosaic ImmunoEngineering Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Mosaic ImmunoEngineering Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

CPMV revenue · 4 questions

CPMV's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

CPMV revenueCPMV annual revenuewhat is CPMV revenueCPMV TTM revenue

Source: FMP · Mosaic ImmunoEngineering Inc. SEC filings · GAAP · Mosaic ImmunoEngineering Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026